Vaccination against human papillomaviruses
Authors:
MUDr. Jiří Sláma; doc. MUDr. Pavel Freitag, CSc.
Authors place of work:
Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
Published in the journal:
Prakt Gyn 2007; 11(1): 30-32
Summary
Persistent high – risk human papillomavirus (HPV) infection causes virtually almost all the cases of cervical cancer. Ability of HPV – L1 capsid protein to form non-infectious virus-like particles was the basis for developing of prophylactic vaccines. They have safety profile, they are highly immunogenic and they have complete type – specific protection against persistent HPV infection and associated lesions in fully vaccinated women.
Key words:
carcinoma of the uterine cervix - human papillomavirus – HPV - vaccine
Zdroje
1. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116: 1167-1173.
2. Mohdavi A, Monk BJ. Vaccines agains human papillomavirus and cervical cancer: Promises and challenges. Onkologist 2005; 10: 528-538.
3. Prendiville W, Davies P. The health professional’s HPV handbook. Abingdon: Taylor and Francis 2004.
4. Freitag P. Papillomavirové infekce v gynekologii. Praha: Triton 1998.
4. Sláma J. Kondylomata accuminata ženského genitálu. Mod Gynek Porod 2005; 14: 231-237.
5. Zhou J, Sun XY, Stenzel DJ et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-257.
7. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from randomised control trial. Lancet 2006; 367: 1247-1255.
8. Villa LL, Costa RL, Petta CA et al. Prophyllactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.
9. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.
10. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
11. Mao C, Koutsky LA, Ault KA et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomised controlled trial. Obstet Gynecol 2006; 107, 18–27.
Štítky
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineČlánok vyšiel v časopise
Practical Gynecology
2007 Číslo 1
Najčítanejšie v tomto čísle
- Bronchial Asthma in Pregnancy
- Optimal management in patients undergoing caesarean section in spinal anaesthesia
- Rooming in
- Amniocenthesis: safe invazive method in prenatal diagnostics